Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/28/2016 11/29/2016 11/30/2016 12/01/2016 12/02/2016 Date
5.875(c) 5.625(c) 5.875(c) 5.75(c) 5.875 Last
250 751 217 017 2 684 65 000 24 362 Volume
0.00% -4.26% +4.44% -2.13% +2.17% Change
More quotes
Financials ( GBP)
Sales 2016 2,80 M
EBIT 2016 -2,70 M
Net income 2016 -2,40 M
Debt 2016 5,60 M
Yield 2016 -
Sales 2017 4,10 M
EBIT 2017 -1,60 M
Net income 2017 -1,40 M
Debt 2017 7,40 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 8,04x
EV / Sales2017 5,93x
Capitalization 16,9 M
More Financials
Company
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.The company focuses on developing proprietary protein biomarkers for neurological... 
More about the company
Latest news on PROTEOME SCIENCES PLC
10/31 PROTEOME SCIENCES : Placing and Subscription of 66,258,100 new Ordinary Shares &..
10/31 PROTEOME SCIENCES : Raises GBP3.3 Million In Discounted Placing (ALLISS)
09/22 PROTEOME SCIENCES : Spectrometry Technique Dramatically Enhances Detection of Ke..
09/20 PROTEOME SCIENCES : Stacking the odds in Alzheimer's Disease Drug Development #W..
09/15 PROTEOME SCIENCES : Expects Good Revenue Growth As Loss Widens
09/12PROTEOME SCIENCES PLC : half-yearly earnings release
07/28 PROTEOME SCIENCES : Sales Momentum To Continue After Strong First Half
07/28 PROTEOME SCIENCES : Trading Update and Notice of Results
06/24 PROTEOME SCIENCES : AGM Statement and Result of AGM
06/01 PROTEOME SCIENCES : Publication of Annual Reports and Accounts 2015
More news
Sector news : Bio Therapeutic Drugs
12:36a Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
11/26 Johnson & Johnson approaches Actelion about takeover deal
More sector news : Bio Therapeutic Drugs
Advertisement
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Full-screen chart
Technical analysis trends PROTEOME SCIENCES...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts 0
Average target price 0,12  GBP
Spread / Average Target 109%
Consensus details
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Executive Director
Christopher D. J. Pearce Executive Chairman
Ian H. Pike Chief Operating Officer & Executive Director
Geoffrey John Ellis Secretary, Executive & Finance Director
Malcolm Ward Chief Technical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-63.49%21
AMGEN, INC.-11.25%105 927
GILEAD SCIENCES, INC.-27.17%95 964
CELGENE CORPORATION-0.74%92 148
REGENERON PHARMACEUTIC..-30.82%39 610
ACTELION LTD40.40%20 855
More Results